Ziprasidone

Generic Name
Ziprasidone
Brand Names
Geodon, Zeldox
Drug Type
Small Molecule
Chemical Formula
C21H21ClN4OS
CAS Number
146939-27-7
Unique Ingredient Identifier
6UKA5VEJ6X
Background

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...

Indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...

Associated Conditions
Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
Associated Therapies
-
Clinical Trials
Related News

A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Phase 3
Terminated
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: Ziprasidone
First Posted Date
2008-03-27
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
1
Registration Number
NCT00645229
Locations
🇵🇹

Pfizer Investigational Site, Lisboa, Portugal

A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

Phase 3
Terminated
Conditions
Schizophrenia
Interventions
Drug: Risperidone
Drug: Ziprasidone
First Posted Date
2008-03-27
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
240
Registration Number
NCT00645515
Locations
🇪🇸

Pfizer Investigational Site, Madrid, Spain

A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Ziprasidone
Drug: Risperidone
First Posted Date
2008-03-27
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
242
Registration Number
NCT00645372
Locations
🇨🇳

Pfizer Investigational Site, Shanghai, China

Ziprasidone in the Treatment of Borderline Personality Disorder

First Posted Date
2008-03-14
Last Posted Date
2008-03-14
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
60
Registration Number
NCT00635921
Locations
🇪🇸

Department of Psychiatry, Sta. Creu and St. Pau Hospital, Barcelona., Spain

Ziprasidone in the Psychosis Prodrome

Phase 2
Completed
Conditions
Psychosis Prodrome
Interventions
Drug: placebo
Drug: ziprasidone
First Posted Date
2008-03-14
Last Posted Date
2023-03-27
Lead Sponsor
Yale University
Target Recruit Count
51
Registration Number
NCT00635700
Locations
🇺🇸

University of California at Los Angeles, Los Angeles, California, United States

🇺🇸

Beth Israel Deaconess Hospital, Boston, Massachusetts, United States

🇺🇸

University of Massachusetts, Worcester, Massachusetts, United States

and more 8 locations

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
Drug: Ziprasidone
First Posted Date
2008-03-13
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
256
Registration Number
NCT00634348
Locations
🇺🇸

Pfizer Investigational Site, Falls Church, Virginia, United States

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Ziprasidone
Drug: Placebo
First Posted Date
2008-03-12
Last Posted Date
2014-07-03
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
458
Registration Number
NCT00633399
Locations
🇺🇸

Massachusetts General Hospital- Depression Clinical and Research Program, Boston, Massachusetts, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Ziprasidone in Pediatric Bipolar Disorder

Phase 4
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Ziprasidone
First Posted Date
2008-02-25
Last Posted Date
2019-10-22
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
28
Registration Number
NCT00622739
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Treatment of Schizophrenic Patients With Ziprasidone

Completed
Conditions
Schizophrenia
First Posted Date
2007-12-24
Last Posted Date
2021-03-10
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
450
Registration Number
NCT00579670
Locations
🇬🇷

Pfizer Investigational Site, Volos, Greece

A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Ziprasidone
First Posted Date
2007-11-09
Last Posted Date
2014-07-03
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
120
Registration Number
NCT00555997
Locations
🇺🇸

Psychiatric Medicine Associates, L.L.C., Chicago, Illinois, United States

🇺🇸

Massachusetts General Hosptial, Boston, Massachusetts, United States

🇺🇸

Cambridge Health Alliance, Cambridge, Massachusetts, United States

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy